非酒精性脂肪性肝病的发病机制与治疗策略
综述指出非酒精性脂肪性肝病(NAFLD)患病率随全球糖尿病和代谢综合征增加而上升,疾病谱从非酒精性单纯性脂肪肝(NAFL)到非酒精性脂肪性肝炎(NASH),可进展为肝硬化和肝癌。文章回顾了NAFLD的发病机制、临床特征、主要合并症、临床进展与并发症风险,以及可用于优化治疗靶点、加速药物开发的体外和动物模型,并讨论了评估药物疗效的临床试验设计原则和新兴药物开发靶点(包括单药和联合治疗)。
要点
- NAFLD患病率随全球糖尿病和代谢综合征增加而上升。
- NAFLD疾病谱从NAFL到NASH,可进展为肝硬化和肝癌。
- 体外和动物模型有助于优化治疗靶点并加速药物开发。
核心结论
- NAFLD患病率上升与全球糖尿病和代谢综合征增加平行,疾病可进展为肝硬化和肝癌。
- 体外和动物模型可优化治疗靶点并加速药物开发,临床试验设计原则和新兴靶点(单药或联合治疗)旨在阻止或逆转疾病进展。
研究设计与样本
- 综述,回顾NAFLD的发病机制、临床特征、主要合并症、临床进展与并发症风险、体外和动物模型、临床试验设计原则及新兴药物开发靶点。
主要发现
- NAFLD患病率随全球糖尿病和代谢综合征增加而上升。
- NAFLD疾病谱从NAFL到NASH,病程可变,可导致肝硬化和肝癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression.
引用
- Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018. PMID: 29967350. doi:10.1038/s41591-018-0104-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。